Literature DB >> 10356378

Long-term treatment with vigabatrin - 10 years of clinical experience.

A Ylinen1, T Salmenperä, J P Mumford, P J Riekkinen.   

Abstract

This report describes the long-term follow-up of 56 patients with refractory partial epilepsy who, within 3 months of vigabatrin add-on therapy (3 g/day), showed a reduction in monthly seizure frequency of more than 50%. The short-term (6 months) and long-term (5 years) effects of vigabatrin on seizure frequency in this patient cohort have been published separately. The reduction in seizure frequency appeared to be long-lasting in the patients followed-up (n = 36) and, importantly, a significant number of the patients (n = 7) became seizure-free, especially during long-term treatment. Thus, the efficacy of vigabatrin appears to be progressive, at least in patients who show an early response to treatment. These results are consistent with experimental findings that suggest that vigabatrin may have anti-epileptogenic and neuroprotective effects. Copyright 1999 BEA Trading Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356378     DOI: 10.1053/seiz.1998.0260

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  A controlled study of vigabatrin and visual abnormalities.

Authors:  K Manuchehri; S Goodman; L Siviter; S Nightingale
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

3.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.